Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Mount Sinai

Sites in New York, NY

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1101
Shown on this page
12
Current sort
Recently updated
Campus scope
Mount Sinai, New York, NY
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Mount Sinai, New York, NY. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 637–648 of 1,101 matching trials with a site at Mount Sinai, New York, NY.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 1 Interventional

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7566802 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors

NCT06031441
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Solid Tumors, Recurrent Solid Tumors, Metastatic Solid Tumors
Interventions
RO7566802, Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
6
States / cities
Birmingham, Alabama • New Haven, Connecticut • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers Results available

ProVee Urethral Expander System IDE Study (ProVIDE)

NCT05186740
Site status not listed — check the official record
View directory record Official record
Conditions
BPH With Symptomatic Lower Urinary Tract Symptoms
Interventions
ProVee Urethral Expander System, Urethral Access Sheath
Device · Procedure
Lead sponsor
ProVerum Medical
Industry
Eligibility
45 Years and older · Male only
Enrollment
221 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2028
U.S. locations
14
States / cities
Sacramento, California • Hialeah, Florida • Palm Coast, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Phase 4 Interventional

Atezolizumab and Bevacizumab in Combination With Y^90 Radioembolization in HCC for Liver Transplant

NCT07059494
Status at this site: Recruiting
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Atezolizumab, Bevacizumab, Y^90 Radioembolization
Drug · Radiation
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Not applicable Interventional

Impella®-Supported PCI in High-Risk Patients With Complex Coronary Artery Disease and Reduced Left Ventricular Function

NCT04763200
Site status not listed — check the official record
View directory record Official record
Conditions
Left Ventricular Dysfunction, Coronary Artery Disease
Interventions
Impella CP® / Impella CP® with SmartAssist® / Impella 2.5®, IABP Intra-aortic balloon pump
Device
Lead sponsor
Abiomed Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
1,252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
83
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Phase 2 Interventional

Phase 2b Study of RPT904 as Monotherapy in Participants With IgE-Mediated Food Allergy

NCT07220811
Status at this site: Recruiting
View directory record Official record
Conditions
Ig-E Mediated Food Allergy
Interventions
RPT904, Placebo
Drug · Other
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
12 Years to 55 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
22
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Not yet recruiting Early Phase 1 Interventional

Iberdomide (CC-220) Priming to Improve T Cell Fitness Prior to Leukapheresis for Chimeric Antigen Receptor T Cell (CAR-T) Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)

NCT07727668
Site status not listed — check the official record
View directory record Official record
Conditions
Multiple Myeloma, Relapsed/Refractory Multiple Myeloma
Interventions
Iberdomide, CAR-T Leukapheresis, CAR-T Infusion
Drug · Procedure
Lead sponsor
Shambavi Richard
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Virtual Reality (VR) Self-Hypnosis Software

NCT06398847
Status at this site: Recruiting
View directory record Official record
Conditions
Musculoskeletal Pain, Neuropathic Pain, Neuralgia
Interventions
Virtual Reality headset
Device
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Not yet recruiting Phase 3 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

NCT07728188
Site status not listed — check the official record
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Etentamig, Pomalidomide, Daratumumab, Dexamethasone, Carfilzomib, Teclistamab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
24
States / cities
Tucson, Arizona • Cerritos, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting No phase listed Observational

Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

NCT06999122
Status at this site: Recruiting
View directory record Official record
Conditions
Stroke, Hemorrhagic Stroke
Interventions
Brain Scan
Diagnostic Test
Lead sponsor
EMVision Medical Devices Ltd
Network
Eligibility
22 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
6
States / cities
Los Angeles, California • Jacksonville, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Recruiting Not applicable Interventional

Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF

NCT06099730
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Pulsed Field Ablation (PFA)
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 80 Years
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
6
States / cities
Jonesboro, Arkansas • Boston, Massachusetts • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

NCT06781983
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced or Metastatic Solid Tumors
Interventions
IPH4502
Drug
Lead sponsor
Innate Pharma
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
5
States / cities
Boston, Massachusetts • Hackensack, New Jersey • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2026 · Synced Oct 30, 2026, 4:13 PM EDT
Active, not recruiting Not applicable Interventional Results available

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

NCT04089059
Site status not listed — check the official record
View directory record Official record
Conditions
Heart Failure NYHA Class III
Interventions
Cordella™ Pulmonary Artery Sensor System
Device
Lead sponsor
Endotronix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
738 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
70
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 57 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 30, 2026, 4:13 PM EDT

About this Mount Sinai institution page

What this page lists
ClinicalTrials.gov records that list Mount Sinai in New York, NY as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.